



DOCKET NO.: ISRT-0327/RTS-0327

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, et al.

Application No.: 10/000,213

Filing Date: November 14, 2001

For: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR
EXPRESSION

Confirmation No.: 1275

Group Art Unit: 1635

Examiner: Terra C. Gibbs

EXPRESS MAIL LABEL NO: EV251284338US
DATE OF DEPOSIT: June 9, 2003

EV251284338US

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

RECEIVED
JUN 13 2003
TECH CENTER 1600/2900

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, therefore:
- Certification in Accordance with § 1.97(e) is attached; or
- The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
- Certification in Accordance with § 1.97(e) is attached;
- or
- The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- EXCEPT THAT:
- In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- Copies of references [**list as appropriate**] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated May 7, 2003 (Number 19 on the PTO-1449), which indicates the references considered to be relevant.


There are no listed references which are not in the English language.

Date: 6/9/03

Phillip A. Singer
Phillip A. Singer
Registration No. 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

c 2003 WW



-1-1


Sheet 1 of 2

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISRT-0327/ RTS-0327	Application No. 10/000,213
	Applicant Brenda F. Baker, et al.	JUN 13 2003 TECH CENTER 1600/2930
	Filing Date November 14, 2001	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	19	Copy of the PCT International Search Report dated May 7, 2003 (PCT/US02/36692)
	20	Branch, A.D., "A good antisense molecule is hard to find," <i>TIBS</i> , February 1998 , 23, 45-50
	21	Fritz, H., et al., "Cationic polystyrene nanoparticles: preparation and characterization of a model drug carrier system for antisense oligonucleotides," <i>J. of Colloid and Interface Science</i> , 1997 , 195, 272-288 (Article No. CS975172)
	22	Jen, K-Y., et al., "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , www.StemCells.com , 2000 , 18, 307-319
	23	Weintraub, H.M., et al., "Antisense RNA and DNA," <i>Scientific American</i> , January 1990 , 40-46

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Sheet 2 of 2

Form PTO-1449 Modified	Docket No. ISRT-0327/ RTS-0327	Application No. 10/000,213
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	RECEIVED JUN 13 2001 TECH CENTER 160	
U.S. Department of Commerce Patent and Trademark Office	Filing Date November 14, 2001	Group 1635

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

EXAMINER	DATE CONSIDERED
-----------------	------------------------